Raynaud’s phenomenon is a condition where blood vessels in the fingers and toes temporarily narrow in response to cold or stress, cutting off blood flow and causing dramatic color changes in the skin. It affects up to 20% to 30% of women and is far less common in men, with a female-to-male ratio of about 9 to 1. Most people with Raynaud’s have a mild, manageable form, but in some cases it signals an underlying autoimmune disease that needs attention.
What Happens During an Episode
Everyone’s body reduces blood flow to the skin in cold temperatures to conserve heat. In Raynaud’s, that reflex is exaggerated. The small arteries supplying your fingers (and sometimes toes, ears, or nose) clamp down far more than necessary, essentially starving the tissue of oxygen for minutes at a time.
A classic episode follows a three-color sequence. First, the affected fingers turn white as blood flow stops. Then they shift to blue as the small amount of trapped blood loses its oxygen. Finally, when the vessels reopen and blood rushes back in, the fingers turn red and you may feel throbbing, tingling, or burning. Not everyone experiences all three phases. Some people only notice the white or blue stage before things return to normal. Episodes typically last 15 to 20 minutes once you warm up or the stress passes.
Primary vs. Secondary Raynaud’s
The distinction between primary and secondary Raynaud’s matters because the two forms behave very differently.
Primary Raynaud’s is the more common type. It tends to appear in teenagers or young adults, runs in families, and exists on its own without any associated disease. Episodes are uncomfortable but rarely cause lasting damage. Interestingly, research shows that people with primary Raynaud’s don’t adapt to repeated stress the way healthy people do. Their nervous system keeps overreacting to cold or emotional triggers rather than learning to dial down its response over time.
Secondary Raynaud’s is driven by another condition, most often an autoimmune disease. The most commonly linked diseases are scleroderma, lupus, rheumatoid arthritis, inflammatory myositis, and Sjögren’s disease. In these cases, the blood vessels themselves are often structurally damaged by inflammation, making episodes more severe and the risk of complications significantly higher. Secondary Raynaud’s can also develop from repetitive vibration injuries (like years of using power tools), certain medications, and smoking.
How Doctors Tell the Difference
If you describe the classic color changes to a doctor, the next question is whether something else is going on beneath the surface. One of the most useful tools for sorting this out is nailfold capillaroscopy, a painless exam where a magnifying instrument looks at the tiny blood vessels along the base of your fingernails. In primary Raynaud’s, these capillaries look normal. In secondary Raynaud’s, especially when linked to scleroderma, the capillaries show distinctive patterns of enlargement, bleeding, and dropout. This test became part of the formal classification criteria for scleroderma in 2013 and is now a routine investigation in rheumatology clinics.
Blood tests for specific antibodies can also point toward an underlying autoimmune condition. Your doctor will typically check for markers associated with lupus, scleroderma, and related diseases, particularly if your Raynaud’s started after age 30, affects your thumbs, or causes skin sores.
Managing Episodes Day to Day
For most people with primary Raynaud’s, the first line of defense is practical: dress in layers, wear insulated gloves and warm socks, and keep hand warmers available. Even reaching into a cold refrigerator or holding a cold drink can trigger an episode, so small adjustments like using insulated cup sleeves or wearing thin gloves while handling frozen food make a real difference. Quitting smoking is critical for anyone with Raynaud’s, since nicotine constricts blood vessels and directly worsens episodes.
Stress management matters too. Since emotional stress triggers the same sympathetic nervous system overreaction as cold, techniques like slow breathing or biofeedback training can reduce the frequency and severity of attacks for some people.
When Medication Is Needed
When lifestyle changes aren’t enough, calcium channel blockers are the standard first-line medication. These drugs relax the smooth muscle in artery walls, making it harder for the vessels to clamp shut. The most commonly prescribed options belong to a subclass that selectively targets blood vessels rather than the heart, making them well-suited for this purpose. European rheumatology guidelines from 2023 continue to recommend nifedipine (a calcium channel blocker) as the go-to choice for Raynaud’s linked to scleroderma.
If calcium channel blockers aren’t effective or cause side effects like headaches or ankle swelling, a class of drugs originally developed for erectile dysfunction (PDE5 inhibitors) is the next option. These also widen blood vessels and are now recommended in European guidelines for scleroderma-related Raynaud’s. For severe cases that don’t respond to pills, intravenous infusions of a prostacyclin drug can be given in a clinic setting to open up the smallest blood vessels.
Complications in Severe Cases
Primary Raynaud’s almost never causes permanent tissue damage. Secondary Raynaud’s, particularly when tied to scleroderma, is a different story.
Digital ulcers, which are open sores on the fingertips caused by prolonged lack of blood flow, develop in roughly 30% to 50% of scleroderma patients. These ulcers heal slowly and are prone to infection. Among those with persistent digital ulcers, about 30% go on to lose tissue permanently. Amputation of one or more fingers due to severe blood flow loss has been reported in around 20% of scleroderma patients, with about 9% losing multiple digits.
Risk factors that predict worse outcomes include early disease onset, smoking, delayed treatment, and the presence of certain antibodies in the blood. Patients who have both small-vessel and large-vessel disease in the hands face the highest risk of needing amputation. This is why identifying secondary Raynaud’s early and treating the underlying disease aggressively can make a meaningful difference in long-term outcomes.
Advanced Interventions for Severe Disease
For people with scleroderma-related Raynaud’s who develop digital ulcers despite medication, several specialized treatments have emerged. Botulinum toxin injections into the hand have shown promise in small studies, with patients reporting improved hand function and better blood flow recovery after cold exposure. In one study of 17 scleroderma patients who underwent digital sympathectomy, a procedure that strips away the nerve fibers causing vessel constriction, 92% of hands had significant pain improvement and all ulcers healed. Topical nitroglycerin applied directly to ulcers is another option to increase local blood flow.
Fat grafting, where a patient’s own fat tissue is injected into the hands, is an emerging approach. The transplanted cells appear to promote new blood vessel growth and reduce inflammation, though this technique is still being refined.